Lifecore Biomedical, Inc. (LFCR): R&D Expense
$8.26M
Year ended 2025-05-25
+1.8%
3-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-05-25 | $8.26M | -3.7% | 2025-08-07, From 2024-05-27 |
| 2024-05-26 | $8.57M | -1.8% | 2025-08-07, From 2023-05-29 |
| 2023-05-28 | $8.74M | +11.4% | 2024-08-26, From 2022-05-30 |
| 2022-05-29 | $7.84M | +17.3% | 2024-08-26, From 2021-05-31 |
| 2021-05-30 | $6.68M | n/c | 2024-03-20, From 2020-06-01 |
| 2020-05-31 | $7.58M | n/c | 2023-03-16, From 2019-05-27 |
| 2019-05-26 | $11.47M | -10.4% | 2021-07-29, From 2018-05-28 |
| 2018-05-27 | $12.80M | +35.1% | 2020-08-14, From 2017-05-29 |
| 2017-05-28 | $9.47M | +31.1% | 2019-08-01, From 2016-05-30 |
| 2016-05-29 | $7.23M | +3.4% | 2018-08-09, From 2015-06-01 |
| 2015-05-31 | $6.99M | -3.0% | 2018-03-15, From 2014-05-26 |
| 2014-05-25 | $7.20M | -22.5% | 2016-08-01, From 2013-05-27 |
| 2013-05-26 | $9.29M | -3.4% | 2015-07-31, From 2012-05-28 |
| 2012-05-27 | $9.62M | +3.8% | 2014-08-01, From 2011-05-30 |
| 2011-05-29 | $9.28M | +112.7% | 2013-08-07, From 2010-05-31 |
| 2010-05-30 | $4.36M | n/a | 2012-08-08, From 2009-06-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Lifecore Biomedical, Inc. (LFCR) | 2025-05-25 | $8.26M | -3.7% |
| Xencor Inc (XNCR) | 2025-12-31 | $239.43M | +5.2% |
| Gyre Therapeutics, Inc. (GYRE) | 2025-12-31 | $13.70M | +13.9% |
| Karyopharm Therapeutics Inc. (KPTI) | 2025-12-31 | $125.62M | -12.3% |
| Elite Pharmaceuticals Inc (ELTP) | 2026-03-31 | $5.74M | -27.9% |
| Macrogenics Inc (MGNX) | 2025-12-31 | $147.17M | -16.9% |
| UroGen Pharma Ltd. (URGN) | 2025-12-31 | $67.11M | +17.4% |
| Theravance Biopharma, Inc. (TBPH) | 2025-12-31 | $37.41M | -0.6% |
| Heron Therapeutics, Inc. (HRTX) | 2025-12-31 | $12.43M | -25.5% |
Compare LFCR, XNCR, GYRE, KPTI side by side · Screen every company in Pharmaceutical Preparations ↗